In Japan, the standard of care for achieving hemostasis in patients with AHA is to use bypassing agents such as recombinant activated factor VII (rFVIIa), activated prothrombin complex concentrate (aPCC), and plasma-derived activated factor VII/factor X complex concentrate (pd-FVIIa/FX), the latter of which is only available in Japan [10]. The gene discussed is F10; the disease is autoimmune hemolytic anemia.